Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2023-09-01
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: This study aims to evaluate the acute effects of caffeine intake on strength, power, muscle endurance, and muscle electrical activity in young adults. It will also analyze the influence of circadian rhythms (morning vs. afternoon) on exercise performance (bench press vs. squat).
Methods: Twelve healthy, physically active participants will be recruited for the study. Using a triple-blind, crossover, randomized, and controlled design, participants will ingest either caffeine (3 mg/kg body mass) or a placebo (maltodextrin, 3 mg/kg) 60 minutes before the trial. Muscular strength, power, and endurance performance will then be assessed through 1RM tests, and at 25%, 50%, 75%, and 90% of 1RM, along with muscle endurance tests at 65% of 1RM, for both squat and bench press exercises. EMG will be used to measure skeletal muscle electrical activity during the tests. The experimental sessions will be conducted in the morning (8:00 am to 10:00 am) and the afternoon (4:30 pm to 6:30 pm).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reproducibility of Acute Caffeine Effect
NCT06606639
Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
NCT07001176
Caffeine and Resistance Training in Older Adults
NCT06618261
Caffeine, CYPA12 and Resistance Exercise
NCT06610110
Caffeine and Sport Climbing Performance
NCT07333443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caffeine - Morning
Caffeine
Acute caffeine intake (3 mg/kg)
Caffeine - Evening
Caffeine
Acute caffeine intake (3 mg/kg)
Placebo - Morning
Placebo
Acute placebo intake (3 mg/kg of maltodextrin)
Placebo - Evening
Placebo
Acute placebo intake (3 mg/kg of maltodextrin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caffeine
Acute caffeine intake (3 mg/kg)
Placebo
Acute placebo intake (3 mg/kg of maltodextrin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) \< 25 kg/m².
* Resistance-trained individuals (more than 2 years of structured training).
* Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
* Participants must be able to perform the tests described in the following section.
Exclusion Criteria
* Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
* Sedentary habits (less than 150 minutes/week of moderate exercise).
* Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
* Engaging in strenuous exercise within 48 hours prior to the tests.
* Failure to replicate the same food intake on both experimental days.
* Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alcala
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alberto Pérez-López
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIP/2023/4/093_2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.